| Predicate |
Object |
| contentType |
Comment|Editorial|Research Support, U.S. Gov't, P.H.S.|Review |
| endingPage |
1466 |
| issn |
0021-972X
1945-7197 |
| issueIdentifier |
4 |
| pageRange |
1462-1466 |
| publicationName |
The Journal of clinical endocrinology and metabolism |
| startingPage |
1462 |
| hasFundingAgency |
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_5a0eb2fadabf1dffb4d70280b760adba
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_c81c82b4ad9caa060230b3c9689699b7 |
| isSupportedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_1cb9dcf8e7ccdffd573ff641e48d52c4
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_6e1fa024c09090442e32c83ee15c93cf |
| bibliographicCitation |
Wang C, Swerdloff RS. Should the nonaromatizable androgen dihydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause? J Clin Endocrinol Metab. 2002 Apr;87(4):1462–6. doi: 10.1210/jcem.87.4.8488. PMID: 11932265. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_16996b793a3c76f0685e3135b9728d19
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d5807d9a4894311a36e22da1d9412d5c |
| date |
2002-04-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| identifier |
https://doi.org/10.1210/jcem.87.4.8488
https://pubmed.ncbi.nlm.nih.gov/11932265 |
| isPartOf |
https://portal.issn.org/resource/ISSN/0021-972X
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/4624
https://portal.issn.org/resource/ISSN/1945-7197 |
| language |
English |
| source |
https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/ |
| title |
Should the Nonaromatizable Androgen Dihydrotestosterone Be Considered as an Alternative to Testosterone in the Treatment of the Andropause? |
| discusses |
http://id.nlm.nih.gov/mesh/M0021196
http://id.nlm.nih.gov/mesh/M0020414
http://id.nlm.nih.gov/mesh/M0001106 |
| discussesAsDerivedByTextMining |
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5995
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6013
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10635 |